Mannatech, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020, compared with fiscal 2019. This is an annual filing; standalone fourth-quarter results are not clearly provided in the supplied filing text.
Business context
Mannatech develops and sells nutritional supplements, skin-care and anti-aging, and weight-management products, primarily through independent associates and preferred customers in international markets. It also sells online in mainland China through a cross-border e-commerce model. The company reported one operating segment. Its network had approximately 183,000 active associate and preferred-customer positions, up from 169,000 in 2019.
Financial performance
| Metric | FY2020 | FY2019 | Change |
|---|---|---|---|
| Net sales | $151.4 million | $157.7 million | Down 4.0% |
| Gross profit / margin | $115.9 million / 76.5% | $126.2 million / 80.0% | Profit down 8.1%; margin down 3.5 percentage points |
| Operating income / margin | $4.5 million / 3.0% | $6.4 million / 4.1% | Down 30.2% |
| Income before taxes | $5.7 million | $5.7 million | Approximately flat |
| Net income | $6.3 million | $3.3 million | Up $3.0 million |
| Diluted EPS | $2.77 | $1.35 | Up $1.42 |
| Cash from operations | $6.0 million | $4.9 million | Up $1.1 million |
Net income exceeded pretax income in 2020 because the company reported a $0.5 million income-tax benefit, including benefits associated with CARES Act net operating loss carrybacks. In 2019, it recorded $2.4 million of income-tax expense. Other income was $1.2 million in 2020, primarily reflecting foreign-exchange gains, compared with a $0.7 million expense in 2019.
Product sales declined 5.4% to $146.2 million, while pack sales and associate fees increased 82.6% to $4.2 million. Average order value fell to $183 from $190; order volume was down 0.1%. Five leading product groups contributed $82.5 million, or 54.5% of sales, in 2020.
Liquidity, cash flow and capital
- Cash and cash equivalents were $22.2 million at year-end; restricted cash was $5.3 million. Combined cash and restricted cash was $27.5 million, down $3.5 million year over year.
- Working capital was $10.5 million, down from $12.1 million, primarily due to higher accounts payable.
- Cash used in investing was $0.9 million, mainly for computer hardware and software. Cash used in financing was $9.9 million, including $5.9 million for share repurchases and $3.4 million for dividends.
- Balance-sheet borrowings included $0.6 million of notes payable and $0.2 million of finance lease liabilities. Operating lease liabilities were $8.2 million. A $2.2 million Paycheck Protection Program loan received in April 2020 was repaid in full that month.
- Management said existing liquidity and operating cash flows should fund normal operations for the next 12 months, while noting that sales, expenses and pandemic effects could affect that assessment.
Changes, outlook and key risks
On a constant-currency basis, sales decreased 2.7%; unfavorable foreign exchange reduced reported sales by $2.1 million. Americas sales fell 6.5% and Asia/Pacific sales fell 4.1%; EMEA sales rose 5.1%. Gross margin weakened amid value pricing, higher logistics costs and currency effects. Lower payroll, travel and other operating costs partly offset lower gross profit. COVID-19 disrupted in-person events and sales meetings and caused raw-material and shipping challenges; management said these factors could continue to affect 2021 sales and liquidity. No quantified revenue or earnings guidance is provided.
- Business and regulatory exposure: Revenue depends on associate recruitment, retention and productivity. Network-marketing rules and product-claim requirements vary across markets; regulatory changes or associate misconduct could lead to restrictions, costs or penalties.
- Supply and product concentration: All products are made by third parties; the company cited no alternative suppliers for Arabinogalactan and Manapol. A single aloe-based supply agreement requires $7.8 million of purchases through 2022. The five leading product groups generated 54.5% of sales.
- Foreign exchange and geographic concentration: 77.7% of sales were outside the United States. The company does not hedge currency exposures. It also disclosed a concentration of cash and net assets in South Korea.
- Litigation: A Korean product-liability claim seeks approximately $90,000; a separate China claim seeks approximately $286,600. Both remained open at filing, and the company said outcomes could not be estimated. A separate China product claim was upheld in the company’s favor on appeal and considered closed. No legal reserve was deemed necessary at year-end.
- Other unusual items: The company repurchased 294,117 shares in a $5.0 million tender offer and paid a $1.00-per-share special dividend in addition to its quarterly dividend. A Korean customs assessment dispute became final against the subsidiary in December 2020; the $1.0 million assessment had been paid in 2014.
Important facts for investors to verify
- Whether lower order values, regional sales declines and weaker gross margin persist after FY2020.
- How the pandemic, logistics costs and dependence on third-party suppliers affect product availability and 2021 cash generation.
- Whether the tax benefit and foreign-exchange gains in 2020 are repeatable; they materially contributed to the year-over-year net-income increase.
- The status and potential financial exposure of the remaining product-liability claims and ongoing tax matters.
- Whether liquidity remains adequate after dividends, repurchases, lease obligations and the $7.8 million minimum purchase commitment.